Zhuhai Rundu Pharmaceutical Past Earnings Performance
Past criteria checks 1/6
Zhuhai Rundu Pharmaceutical has been growing earnings at an average annual rate of 2.3%, while the Pharmaceuticals industry saw earnings growing at 9.2% annually. Revenues have been growing at an average rate of 1.9% per year. Zhuhai Rundu Pharmaceutical's return on equity is 5.7%, and it has net margins of 5.2%.
Key information
2.3%
Earnings growth rate
2.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 1.9% |
| Return on equity | 5.7% |
| Net Margin | 5.2% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Zhuhai Rundu Pharmaceutical's (SZSE:002923) Dividend Is Being Reduced To CN¥0.20
May 29
There May Be Reason For Hope In Zhuhai Rundu Pharmaceutical's (SZSE:002923) Disappointing Earnings
May 05There's Reason For Concern Over Zhuhai Rundu Pharmaceutical Co., Ltd.'s (SZSE:002923) Massive 32% Price Jump
Mar 05Revenue & Expenses Breakdown
How Zhuhai Rundu Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1,292 | 67 | 393 | 129 |
| 30 Sep 23 | 1,326 | 119 | 415 | 108 |
| 30 Jun 23 | 1,369 | 150 | 420 | 94 |
| 31 Mar 23 | 1,409 | 158 | 439 | 91 |
| 31 Dec 22 | 1,372 | 155 | 462 | 92 |
| 30 Sep 22 | 1,319 | 153 | 471 | 86 |
| 30 Jun 22 | 1,274 | 150 | 476 | 90 |
| 31 Mar 22 | 1,189 | 143 | 462 | 87 |
| 01 Jan 22 | 1,190 | 140 | 476 | 84 |
| 30 Sep 21 | 1,157 | 114 | 475 | 83 |
| 30 Jun 21 | 1,172 | 124 | 475 | 81 |
| 31 Mar 21 | 1,259 | 139 | 522 | 88 |
| 31 Dec 20 | 1,253 | 136 | 528 | 94 |
| 30 Sep 20 | 1,299 | 131 | 612 | 105 |
| 30 Jun 20 | 1,324 | 130 | 666 | 105 |
| 31 Mar 20 | 1,337 | 122 | 712 | 104 |
| 31 Dec 19 | 1,360 | 119 | 745 | 115 |
| 30 Sep 19 | 1,312 | 125 | 737 | 105 |
| 30 Jun 19 | 1,258 | 120 | 717 | 101 |
| 31 Mar 19 | 1,162 | 116 | 664 | 90 |
| 01 Jan 19 | 1,044 | 107 | 608 | 66 |
| 30 Sep 18 | 970 | 103 | 514 | 87 |
| 30 Jun 18 | 884 | 97 | 439 | 67 |
| 31 Mar 18 | 816 | 92 | 382 | 55 |
| 31 Dec 17 | 779 | 91 | 347 | 45 |
| 31 Dec 16 | 652 | 87 | 319 | 0 |
| 31 Dec 15 | 578 | 71 | 294 | 0 |
| 31 Dec 14 | 524 | 60 | 272 | 0 |
| 31 Dec 13 | 434 | 59 | 217 | 0 |
Quality Earnings: 002923 has a large one-off loss of CN¥43.1M impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: 002923's current net profit margins (5.2%) are lower than last year (11.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 002923's earnings have grown by 2.3% per year over the past 5 years.
Accelerating Growth: 002923's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 002923 had negative earnings growth (-57%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-0.9%).
Return on Equity
High ROE: 002923's Return on Equity (5.7%) is considered low.